CD56(bright) natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results

Randomized trials have conclusively shown higher rates of chronic graft-versus-host disease with filgrastim-stimulated apheresis peripheral blood as a donor source than unstimulated bone marrow. The Canadian Blood and Marrow Transplant Group conducted a phase 3 study of adults who received either fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kariminia, Amina, Ivison, Sabine, Ng, Bernard, Rozmus, Jacob, Sung, Susanna, Varshney, Avani, Aljurf, Mahmoud, Lachance, Sylvie, Walker, Irwin, Toze, Cindy, Lipton, Jeff, Lee, Stephanie J., Szer, Jeff, Doocey, Richard, Lewis, Ian, Smith, Clayton, Chaudhri, Naeem, Levings, Megan K., Broady, Raewyn, Devins, Gerald, Szwajcer, David, Foley, Ronan, Mostafavi, Sara, Pavletic, Steven, Wall, Donna A., Couban, Stephan, Panzarella, Tony, Schultz, Kirk R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664398/
https://www.ncbi.nlm.nih.gov/pubmed/28935847
http://dx.doi.org/10.3324/haematol.2017.170928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664398/
https://www.ncbi.nlm.nih.gov/pubmed/28935847
http://dx.doi.org/10.3324/haematol.2017.170928

Ejemplares similares